N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation

被引:121
作者
Chytil, Petr [1 ]
Etrych, Tomas [1 ]
Kriz, Jaroslav [1 ]
Subr, Vladimir [1 ]
Ulbrich, Karel [1 ]
机构
[1] Acad Sci Czech Republ, Inst Macromol Chem, Vvi, CR-16206 Prague 6, Czech Republic
关键词
HPMA copolymers; Drug carriers; RAFT polymerisation; Controlled drug release; Drug targeting; Cancer; HPMA COPOLYMERS; DIBLOCK COPOLYMERS; CARBON NANOTUBES; BLOCK-COPOLYMERS; IN-VITRO; POLY(N-(2-HYDROXYPROPYL)METHACRYLAMIDE); FUNCTIONALIZATION; RELEASE; LINKAGE; ACID;
D O I
10.1016/j.ejps.2010.08.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Controlled radical reversible addition-fragmentation chain transfer (RAFT) polymerisation was used to prepare water-soluble polymer-drug carriers based on copolymers of N-(2-ydroxypropyl)methacrylamide (HPMA) with a hydrazide group-containing monomer, showing well-defined structure with narrow molecular weight distribution (approx. 1.1-1.2). The anticancer therapeutic doxorubicin was bound to the polymeric carrier by a hydrazone bond, enabling pH-controlled release under mildly acid conditions that mimics the environment in endosomes/lysosomes of tumour cells. RAFT polymerisation facilitated the synthesis of semitelechelic copolymers, which were used in the synthesis of monoclonal anti-CD20 antibody-polymer-drug conjugate designed for cell-specific tumour targeting. They were also used for producing a biodegradable high-molecular-weight graft polymer-drug conjugate that degrade in the presence of glutathione, which is designed for passive targeting to solid tumours. The conjugates exhibited well-defined structures with narrow molecular weight distributions of approx. 1.3 and pH-controlled drug release. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:473 / 482
页数:10
相关论文
共 38 条
[1]  
Barner L., 2008, HDB RAFT POLYM, P455
[2]   From Defined Reactive Diblock Copolymers to Functional HPMA-Based Self-Assembled Nanoaggregates [J].
Barz, M. ;
Tarantola, M. ;
Fischer, K. ;
Schmidt, M. ;
Luxenhofer, R. ;
Janshoff, A. ;
Theato, P. ;
Zentel, R. .
BIOMACROMOLECULES, 2008, 9 (11) :3114-3118
[3]   New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting [J].
Chytil, P. ;
Etrych, T. ;
Konak, C. ;
Sirova, M. ;
Mrkvan, T. ;
Boucek, J. ;
Rihova, B. ;
Ulbrich, K. .
JOURNAL OF CONTROLLED RELEASE, 2008, 127 (02) :121-130
[4]   Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation:: Effect of polymer chain modification [J].
Chytil, Petr ;
Etrych, Tomas ;
Konak, Cestmir ;
Sirova, Milada ;
Mrkvan, Tomas ;
Rihova, Blanka ;
Ulbrich, Karel .
JOURNAL OF CONTROLLED RELEASE, 2006, 115 (01) :26-36
[5]   TISSUE SULFHYDRYL GROUPS [J].
ELLMAN, GL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1959, 82 (01) :70-77
[6]  
Etrych T, 2002, MACROMOL BIOSCI, V2, P43, DOI 10.1002/1616-5195(20020101)2:1<43::AID-MABI43>3.0.CO
[7]  
2-8
[8]   New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage:: synthesis and preliminary in vitro and in vivo biological properties [J].
Etrych, T ;
Jelínková, M ;
Ríhová, B ;
Ulbrich, K .
JOURNAL OF CONTROLLED RELEASE, 2001, 73 (01) :89-102
[9]   N-(2-hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin.: I.: New synthesis, physicochemical characterization and preliminary biological evaluation [J].
Etrych, Tomas ;
Mrkvan, Tomas ;
Chytil, Petr ;
Konak, Cestmir ;
Rihova, Blanka ;
Ulbrich, Karel .
JOURNAL OF APPLIED POLYMER SCIENCE, 2008, 109 (05) :3050-3061
[10]   Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy [J].
Etrych, Tomas ;
Mrkvan, Tomas ;
Rihova, Blanka ;
Ulbrich, Karel .
JOURNAL OF CONTROLLED RELEASE, 2007, 122 (01) :31-38